Beaconlight Capital LLC Sells 14,874 Shares of TransMedics Group, Inc. $TMDX

Beaconlight Capital LLC trimmed its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 33.6% during the 4th quarter, Holdings Channel.com reports. The firm owned 29,344 shares of the company’s stock after selling 14,874 shares during the period. TransMedics Group comprises 2.1% of Beaconlight Capital LLC’s investment portfolio, making the stock its 17th largest position. Beaconlight Capital LLC’s holdings in TransMedics Group were worth $3,570,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TMDX. Guggenheim Capital LLC grew its stake in shares of TransMedics Group by 423.5% in the fourth quarter. Guggenheim Capital LLC now owns 12,542 shares of the company’s stock worth $1,526,000 after acquiring an additional 10,146 shares during the last quarter. Schonfeld Strategic Advisors LLC lifted its holdings in shares of TransMedics Group by 245.8% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 91,065 shares of the company’s stock valued at $11,078,000 after purchasing an additional 64,730 shares in the last quarter. Cetera Investment Advisers lifted its holdings in shares of TransMedics Group by 26.3% during the fourth quarter. Cetera Investment Advisers now owns 10,771 shares of the company’s stock valued at $1,310,000 after purchasing an additional 2,240 shares in the last quarter. Stansberry Asset Management LLC bought a new position in TransMedics Group in the fourth quarter valued at about $245,000. Finally, Trexquant Investment LP lifted its holdings in TransMedics Group by 15.0% in the fourth quarter. Trexquant Investment LP now owns 92,481 shares of the company’s stock valued at $11,250,000 after acquiring an additional 12,080 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the transaction, the director directly owned 16,642 shares in the company, valued at approximately $1,249,148.52. This trade represents a 36.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 6.90% of the company’s stock.

Wall Street Analysts Forecast Growth

TMDX has been the topic of several recent research reports. Stifel Nicolaus decreased their price objective on TransMedics Group from $85.00 to $75.00 and set a “hold” rating on the stock in a research note on Tuesday, May 26th. Piper Sandler cut their price target on TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. UBS Group restated a “hold” rating on shares of TransMedics Group in a report on Tuesday, May 26th. Oppenheimer cut TransMedics Group from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 6th. Finally, Wall Street Zen lowered TransMedics Group from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Six equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $134.00.

TransMedics Group Trading Down 3.4%

Shares of NASDAQ TMDX opened at $73.22 on Thursday. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. The business has a fifty day simple moving average of $84.57 and a two-hundred day simple moving average of $113.51. The firm has a market cap of $2.53 billion, a PE ratio of 16.64 and a beta of 1.91. TransMedics Group, Inc. has a twelve month low of $60.10 and a twelve month high of $156.00.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The firm had revenue of $173.93 million for the quarter, compared to the consensus estimate of $174.44 million. During the same period last year, the firm earned $0.70 earnings per share. The company’s revenue for the quarter was up 21.2% on a year-over-year basis. Analysts expect that TransMedics Group, Inc. will post 1.98 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.